Ovarian cancer: can a second round of niraparib after surgery keep tumors at bay?
NCT ID NCT06180356
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether giving the drug niraparib again after surgery can help women with ovarian cancer whose disease has come back in just a few spots. About 30 participants will take niraparib pills daily until their cancer grows or side effects become too much. The main goal is to see how long they live without their cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
niraparib (a PARP inhibitor oral tablet)
What this could lead to
If successful, this could offer a new treatment option for ovarian cancer patients whose disease has come back in a few spots after initial therapy.
What could go wrong
This is a small, early-phase study with only 30 patients. It may not show a clear benefit, and side effects from niraparib (like low blood counts) are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Complejo Hospitalario Universitario A Coruña (CHUAC)
RECRUITINGA Coruña, Spain
-
Complejo Hospitalario de Jaén
RECRUITINGJaén, Spain
-
Hospital Arnau de Vilanova de Valencia
RECRUITINGValencia, Spain
-
Hospital Universitari Sant Joan de Reus
RECRUITINGTarragona, Spain
-
Hospital Universitari Vall D'Hebron
RECRUITINGBarcelona, Spain
-
Hospital Universitari i Politècnic La Fe
RECRUITINGValencia, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, Spain
-
Hospital Universitario Central de Asturias (HUCA)
RECRUITINGOviedo, Spain
-
Hospital Universitario La Paz
RECRUITINGMadrid, Spain
-
Hospital Universitario Ramón y Cajal
RECRUITINGMadrid, Spain
-
Hospital Universitario Virgen Macarena
RECRUITINGSeville, Spain
-
Hospital Universitario Virgen de la Victoria
RECRUITINGMálaga, Spain
-
Hospital de Cruces
RECRUITINGBarakaldo, Spain
-
Institut Català d' Oncologia Girona (ICO)
RECRUITINGGirona, Spain